LLY supply chain intelligence for Eli Lilly and Company: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Eli Lilly and Company (LLY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INCY | Incyte Corporation | 95% | Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY gra… |
| ACRS | Aclaris Therapeutics, Inc. | 92% | Reciprocal relationship from ACRS graph: OMERS acquired a portion of the royalty payable by Lilly to us for worldwide net sales of OLUMIANT for the treatment of alopecia areata from April 1, 2024 thr… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| VTYX | Ventyx Biosciences Inc | 92% | Reciprocal relationship from VTYX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from VTYX graph: Pursuant to the Merger Agreement, and upon the terms and subject to the condi… |
| CHUGAI-PHARMACEUTICAL-CO-LTD | CHUGAI-PHARMACEUTICAL-CO-LTD | 90% | Chugai receives tiered royalty payments on worldwide net sales ranging in percentages from mid single digits to low teens, which we recognize as cost of sales. |
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 90% | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| GENENTECH-INC | GENENTECH-INC | 90% | Roche receives tiered royalty payments on worldwide net sales ranging in percentages from high single digits to high teens, which we recognize as cost of sales. |
| CRNX | Crinetics Pharmaceuticals, Inc. | 85% | Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRNX gra… |
| OPK | OPKO Health, Inc. | 85% | Reciprocal relationship from OPK graph: 6, through its subsidiary Waratah Pharmaceuticals Inc., entered into a worldwide license agreement with Eli Lilly and Company (“Eli Lilly”) to develop and comm… |
| PRQR | ProQR Therapeutics N.V. | 85% | Reciprocal relationship from PRQR graph: — ( ) The effect of changes in foreign exchange rates — — — Other changes Interest expense — — Interest paid — — — Effect of w… |
| ACIU | AC Immune SA | 72% | Reciprocal relationship from ACIU graph: scussed below). Further, the Civil Monetary Penalties Law imposes penalties against any person or entity that, among other things, is determined to have prese… |
| AKTS | Aktis Oncology, Inc. | 72% | Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from AKTS gra… |
| ALEC | Alector, Inc. | 72% | Reciprocal relationship from ALEC graph: t on our business and could potentially cause us to cease operations. We may not be successful in our efforts to further develop our current product candidate… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ALNY gra… |
| AXSM | Axsome Therapeutics, Inc. | 72% | Reciprocal relationship from AXSM graph: DA issued more than 100 enforcement letters to pharmaceutical companies and compounding firms, alleging that certain promotional communications and DTC advert… |
| BCYC | Bicycle Therapeutics plc | 72% | Reciprocal relationship from BCYC graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BCYC graph: dministered, the radiopharmaceuticals are designed to target tumor antigens t… |
| BIOA | BioAge Labs, Inc. | 72% | Reciprocal relationship from BIOA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA gra… |
| BYSI | BeyondSpring Inc. | 72% | Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BYSI gra… |
| CRIS | Curis, Inc. | 72% | Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, bot… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX gra… |
| CTNM | Contineum Therapeutics, Inc. | 72% | Reciprocal relationship from CTNM graph: om, or engaging in the sale or supply of products and services to, U.S. sanctioned countries, governments, persons and entities. Violations of Trade Laws can … |
| DAWN | Day One Biopharmaceuticals Inc | 72% | Reciprocal relationship from DAWN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from DAWN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from DAWN gra… |
| DSGN | Design Therapeutics, Inc. | 72% | Reciprocal relationship from DSGN graph: riffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively m… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the p… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary … |
| ELAN | Elanco Animal Health Incorporated | 72% | Reciprocal relationship from ELAN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ELAN graph: services to prevent and treat disease in farm animals and pets. We partner wi… |
| FBIO | Fortress Biotech, Inc. | 72% | Reciprocal relationship from FBIO graph: ecognize additional shares received pursuant to its anti-dilution rights under the APA, resulting in an increase in estimated fair value of $ 15.1 million whi… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FDMT gra… |
| FHTX | Foghorn Therapeutics Inc. | 72% | Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from FHTX gra… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $281,860 across 2 awards. 36C25026N0080 AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN; 36C26226N0579 F-18 AMYVID B+4 | Qwen corre… |
| ACIU | AC Immune SA | 92% | Reciprocal relationship from ACIU graph: Reciprocal relationship from LLY graph: Reciprocal relationship from ACIU graph: ave achieved and our goal of a close working relationship with the regulatory… |
| BOEHRINGER-INGELHEIM | BOEHRINGER-INGELHEIM | 92% | Jardiance revenue outside the U.S. included one-time benefits of $250 million in Q1 2026 compared to $370 million in Q1 2025, associated with the company's collaboration with Boehringer Ingelheim. |
| IMRX | Immuneering Corporation | 92% | Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from IMRX gra… |
| INCY | Incyte Corporation | 92% | Reciprocal relationship from INCY graph: Reciprocal relationship from LLY graph: Reciprocal relationship from INCY graph: entered into a license, development and commercialization agreement with Eli … |
| SPRB | Spruce Biosciences, Inc. | 92% | Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SPRB gra… |
| ALMIRALL-S-A | ALMIRALL-S-A | 90% | We receive tiered royalty payments on net sales in Europe ranging in percentages from low double digits to low twenties, which we recognize as collaboration and other revenue. |
| FHTX | Foghorn Therapeutics Inc. | 90% | Reciprocal relationship from FHTX graph: Concurrent with the Lilly Collaboration Agreement, we also entered into a stock purchase agreement (the "Lilly SPA") with Lilly whereby we issued and sold Lil… |
| ACRS | Aclaris Therapeutics, Inc. | 80% | Reciprocal relationship from ACRS graph: Under the terms of the royalty purchase agreement, we sold to OMERS a portion of the future royalty payments and the remaining anniversary milestone payments … |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | Reciprocal relationship from AMPH graph: Reciprocal relationship from LLY graph: marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of the Jardiance produ… |
| AMPH | Amphastar Pharmaceuticals, Inc. | 72% | marketing, selling, and administrative expense, respectively. We receive a royalty on net sales of the Jardiance product family in the most significant markets and recognize the royalty as collaborat… |
| BEAM | Beam Therapeutics Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BEAM graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,35… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi, Synjardy, and Trijardy XR. (2) Humalog revenue includes insulin lispro. (3) Basa… |
| BMRN | BioMarin Pharmaceutical Inc. | 72% | Reciprocal relationship from BMRN graph: Reciprocal relationship from LLY graph: 8,190.0 $ 14,667.5 $ 12,333.1 $ 10,351.3 Numbers may not add due to rounding. (1) Jardiance revenue includes Glyxambi,… |
| CAH | Cardinal Health, Inc. | 72% | Reciprocal relationship from CAH graph: Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain w… |
| CAH | Cardinal Health, Inc. | 72% | ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the … |
| CYCN | Cyclerion Therapeutics, Inc. | 72% | Reciprocal relationship from CYCN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CYCN graph: rovides for the attachment of an additional six months of marketing protectio… |
| ECOR | electroCore, Inc. | 72% | Reciprocal relationship from ECOR graph: uster and migraine markets by securing broad market acceptance of our prescription gammaCore therapy. We believe that the primary competitive factors in the p… |
| EDSA | Edesa Biotech, Inc. | 72% | Reciprocal relationship from EDSA graph: ly reported that supplies of raw materials and critical components necessary for manufacturing processes have been more challenging and expensive to obtain, a… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements w… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: m in accordance with the FDA’s good clinical practice, or GCP, requirements, or applicable regulatory guidelines in other countries; ● patients who enroll in … |
| MCK | McKesson Corporation | 72% | Reciprocal relationship from MCK graph: Reciprocal relationship from LLY graph: ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain w… |
| MCK | McKesson Corporation | 72% | ng at medical meetings. In addition, we advertise certain products directly to consumers in the U.S., and we maintain websites and other media channels (e.g., social media) with information about our… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGNX graph: Co., Ltd., Merck & Co., Inc., in collaboration with its partner, Daiichi and … |
| MGTX | MeiraGTx Holdings plc | 72% | Reciprocal relationship from MGTX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MGTX graph: acture plasmid DNA – the critical starting material for producing gene therap… |
| MNPR | Monopar Therapeutics Inc. | 72% | Reciprocal relationship from MNPR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MNPR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MNPR gra… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR gra… |
| NVO | Novo Nordisk A/S | 72% | 32.7 Cash value of trust owned insurance contract 1,526.5 — 1,526.5 — — Real estate 24.5 24.5 — — — Other 97.8 23.2 2.1 — 72.5 Total $ 2,580.3 $ 130.1 $ 1,603.5 $ 2.4 $ 844.3 (1) Certain investments … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LLY-DEBT | Debt stack $54.9B | 90% | Market cache reports total debt of $54.9B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| LLY-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 4359 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GANX | Gain Therapeutics, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 1 | ['supplier'] |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CVS | CVS Health Corporation | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 1 | ['customer'] |